New injection trial aims to tame painful, bulging eyes
NCT ID NCT06106828
Summary
This Phase 3 study is testing whether an injectable medication called satralizumab can help people with moderate-to-severe thyroid eye disease. The trial will measure if the treatment reduces eye bulging, eases pain and double vision, and improves quality of life. It involves 127 participants and compares the drug against a placebo to see which is more effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIBILI - Association for Innovation and Biomedical Research on Light
Coimbra, 3000-548, Portugal
-
Beijing Hospital of Ministry of Health
Beijing, 100730, China
-
Beijing Tongren Hospital, Capital Medical University
Beijing, 100730, China
-
Bristol Eye Hospital
Bristol, BS1 2LX, United Kingdom
-
CHNO Hopital des Quinze Vingts
Paris, 75012, France
-
CHU Nantes - Hotel Dieu
Nantes, 44093, France
-
Chung-Ang University Hospital
Seoul, 06973, South Korea
-
Connecticut Eye Consultants, P.C.
Danbury, Connecticut, 06810, United States
-
Fondation Rothschild
Paris, 75019, France
-
Gartnavel General Hospital
Glasgow, G12 0YN, United Kingdom
-
Hadassah MC
Jerusalem, 9112001, Israel
-
Hospital Ramon y Cajal
Madrid, 28031, Spain
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 8907, Spain
-
Hospital Universitario Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Universitario Vall d Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen de la Macarena
Seville, 41007, Spain
-
Hospital Universitario Virgen de las Nieves
Granada, 18012, Spain
-
Hospital Universitario la Fe: Servicio de Oftalmologia
Valencia, 46026, Spain
-
Maidstone Hospital
Maidstone, Kent, ME16 9QQ, United Kingdom
-
Moorfields Eye Hospital NHS Foundation Trust
London, EC1V 2PD, United Kingdom
-
Peking Union Medical College Hospital
Beijing, 100032, China
-
Peking University Third Hospital
Beijing, 100191, China
-
Plastics-Orbit-Neuro
San Diego, California, 92108, United States
-
Profesorskie Centrum Medyczne Spolka Z Ograniczona Odpowiedzialnoscia
Gdansk, 80-180, Poland
-
Rabin MC
Petah Tikva, 4941492, Israel
-
Retina Consultants of Texas
San Antonio, Texas, 78251, United States
-
Royal Liverpool University Hospital
Liverpool, L7 8XP, United Kingdom
-
Samsung Medical Center
Seoul, 135-710, South Korea
-
Scheie Eye Institute
Philadelphia, Pennsylvania, 19104, United States
-
Seoul National University Bundang Hospital
Seongnam-si, 13620, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 003-722, South Korea
-
Sheba medical center
Ramat Gan, Israel
-
Specjalistyczny Osrodek Okulistyczny Oculomedica
Bydgoszcz, 85-316, Poland
-
St James University Hospital
Leeds, LS9 7TF, United Kingdom
-
Sussex Eye Hospital
Brighton, BN2 5BF, United Kingdom
-
Toronto Retina Institute
Toronto, Ontario, M3C 0G9, Canada
-
Universite de Montreal - Hopital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4, Canada
-
University of Alberta
Edmonton, Alberta, Canada
-
University of Illinois Eye and Ear Infirmary
Chicago, Illinois, 60612, United States
-
Vanderbilt Eye Institute
Nashville, Tennessee, 37232-8808, United States
-
Xi'an Fourth Hospital
Xi'an, 710004, China
Conditions
Explore the condition pages connected to this study.